Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Repare Therapeutics Inc (RPTX)

Repare Therapeutics Inc (RPTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,403
  • Shares Outstanding, K 37,001
  • Annual Sales, $ 51,130 K
  • Annual Income, $ -93,800 K
  • 60-Month Beta 0.56
  • Price/Sales 2.28
  • Price/Cash Flow N/A
  • Price/Book 0.66
Trade RPTX with:

Options Overview Details

View History
  • Implied Volatility 293.60% ( -110.67%)
  • Historical Volatility 53.56%
  • IV Percentile 95%
  • IV Rank 61.30%
  • IV High 442.20% on 04/05/24
  • IV Low 58.20% on 06/02/23
  • Put/Call Vol Ratio 999.99
  • Today's Volume 5
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 680
  • Open Int (30-Day) 937

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.10
  • Number of Estimates 5
  • High Estimate 0.14
  • Low Estimate -0.74
  • Prior Year -0.83
  • Growth Rate Est. (year over year) +87.95%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.98 +7.38%
on 04/19/24
4.88 -34.43%
on 03/28/24
-1.33 (-29.36%)
since 03/26/24
3-Month
2.98 +7.38%
on 04/19/24
8.49 -62.31%
on 02/12/24
-3.32 (-50.92%)
since 01/26/24
52-Week
2.98 +7.38%
on 04/19/24
13.85 -76.90%
on 09/20/23
-6.02 (-65.29%)
since 04/26/23

Most Recent Stories

More News
Wall Street Thinks This Cathie Wood Stock Could Jump by 187%

This small-cap biotech stock holds enormous growth potential.

TSLA : 168.29 (-1.11%)
ROKU : 56.35 (-10.28%)
SHOP : 71.33 (+1.11%)
RPTX : 3.20 (+1.59%)
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 1.19% and 19.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

RPTX : 3.20 (+1.59%)
VCEL : 46.05 (+1.32%)
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of 20% and 8.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

MNKD : 4.23 (+1.20%)
RPTX : 3.20 (+1.59%)
How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 214.72%

The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 214.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

RPTX : 3.20 (+1.59%)
Repare Therapeutics Appoints Susan Molineaux, Ph.D., to Its Board of Directors

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the appointment of Susan Molineaux, Ph.D., to its Board...

RPTX : 3.20 (+1.59%)
Repare Therapeutics Presents Initial Clinical Data from the Phase 1/2 TRESR and ATTACC Trials Evaluating Camonsertib in Combination with Three PARP Inhibitors at the 2023 AACR Annual Meeting

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today presented initial data from its ongoing Phase 1/2 TRESR clinical...

RPTX : 3.20 (+1.59%)
Repare Therapeutics Announces Plenary Oral Presentation at the 2023 AACR Annual Meeting on Camonsertib and Additional Data Presentations on RP-6306

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the data from the Phase I/II trials evaluating camonsertib...

RPTX : 3.20 (+1.59%)
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

RPTX : 3.20 (+1.59%)
ALEC : 5.25 (+9.15%)
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the fourth quarter and full year ended...

RPTX : 3.20 (+1.59%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Repare Therapeutics Inc. - RPTX

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Repare Therapeutics Inc. ("Repare" or the "Company") (NASDAQ: RPTX). Such...

RPTX : 3.20 (+1.59%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare...

See More

Key Turning Points

3rd Resistance Point 3.39
2nd Resistance Point 3.31
1st Resistance Point 3.26
Last Price 3.20
1st Support Level 3.13
2nd Support Level 3.05
3rd Support Level 3.00

See More

52-Week High 13.85
Fibonacci 61.8% 9.70
Fibonacci 50% 8.41
Fibonacci 38.2% 7.13
Last Price 3.20
52-Week Low 2.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar